3 Doses versus 2 Doses Cervical Cancer Vaccination Regimen: Cost–Utility Analysis Based on Tropical Southeast Asian Country, Thailand, Situation

Beuy Joob; Viroj Wiwanitkit

doi:10.4103/ijmpo.ijmpo_163_17

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(S 01): S192-S193
DOI: 10.4103/ijmpo.ijmpo_163_17

Letter to Editor

3 Doses versus 2 Doses Cervical Cancer Vaccination Regimen: Cost–Utility Analysis Based on Tropical Southeast Asian Country, Thailand, Situation

Beuy Joob

Sanitation 1 Medical Academic Center, Bangkok, Thailand

,

Viroj Wiwanitkit

Department of Medical Science, Faculty of Medicine, University of Nis, Nis, Serbia

Department of Community Medicine, Dr. D. Y. Patil University, Pune, Maharashtra, India

Department of Biological Science, Joseph Ayo Babalola University, Ikeji-Arakeji, Osun State, Nigeria

References
1 McCance DJ. Human papillomavirus (HPV) infections in the aetiology of cervical cancer. Cancer Surv 1988; 7: 499-506
2 Harper DM, DeMars LR. HPV vaccines – A review of the first decade. Gynecol Oncol 2017; 146: 196-204
3 Donken R, Schurink-Van’t Klooster TM, Schepp RM, van der Klis FR, Knol MJ, Meijer CJ. et al. Immune responses after 2 versus 3 doses of HPV vaccination up to 4½ years after vaccination: An observational study among Dutch routinely vaccinated girls. J Infect Dis 2017; 215: 359-67
4 Hernández-Ávila M, Torres-Ibarra L, Stanley M, Salmerón J, Cruz-Valdez A, Muñoz N. et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother 2016; 12: 30-8
5 Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J. et al. Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014; 32: 725-32
6 Bhatla N, Nene BM, Joshi S, Esmy PO, Poli UR, Joshi G. et al. Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India. Papillomavirus Res 2018; 5: 163-71
7 Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P. et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine 2018; 36: 4783-91
8 Sankaranarayanan R, Bhatla N, Basu P. Current global status and impact of human papillomavirus vaccination: Implications for India. Indian J Med Res 2016; 144: 169-80
9 Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R. et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: A multicentre prospective cohort study. Lancet Oncol 2016; 17: 67-77
10 Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M. et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs. 3 doses in young women: A randomized clinical trial. JAMA 2013; 309: 1793-802
11 Phoolcharoen N, Kantathavorn N, Sricharunrat T, Saeloo S, Krongthong W. A population-based study of cervical cytology findings and human papillomavirus infection in a suburban area of Thailand. Gynecol Oncol Rep 2017; 21: 73-7
12 Widdice LE, Unger ER, Panicker G, Hoagland R, Callahan ST, Jackson LA. et al. Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. Vaccine 2018; 36: 881-9
13 Lamb F, Herweijer E, Ploner A, Uhnoo I, Sundström K, Sparén P. et al. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: A nationwide cohort study. BMJ Open 2017; 7: e015021